Taiho Pharmaceutical's press releases may contain information about prescription drugs including products currently under development, however information contained in the press releases are not intended to constitute promotion, advertisement, or medical advice.
2015
December 17, 2015
Taiho and Meiji Enter Into a Co-marketing Agreement in Japan for TAC-202(bilastine), a Treatment for Allergic Disorders(PDF:554.9 KB)
November 26, 2015
NHI Reimbursement Price Listing and Launch of the Novel Antitumor Agent "Yondelis® IV Infusion"
November 13, 2015
Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan
September 28, 2015
Novel Antitumor Agent "Yondelis® IV Infusion" Approved in Japan for Treatment of Soft Tissue Sarcoma
September 24, 2015
Taiho Pharmaceutical Announces FDA Approval of LONSURF® (trifluridine and tipiracil) for Refractory Metastatic Colorectal Cancer (mCRC)
September 01, 2015
The First Pre-Meal Drink in the Solmack Series "Solmack 5 Herbal Digestive Support" Nationwide Launch in Japan on Monday, September 7
June 26, 2015
ZOSYN® Receives Approval for the Additional Indication of Febrile Neutropenia
June 15, 2015
Taiho Pharmaceutical Co., Ltd. and Servier Enter Into a License Agreement for Development and Commercialization of an Oral Anticancer Drug TAS-102 in Europe
June 01, 2015
Support for modern people in the prime of life! Designated quasi-drug Tiovita Gold α (Alpha) mini-drink to be launched throughout Japan on June 22
May 14, 2015
Results from Global Phase III Trial of TAS-102 (brand name in Japan: "Lonsurf® ") Published in The New England Journal of Medicine
March 20, 2015
Lonsurf® Combination Tablet for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer Receives Approval in Japan for Partial Change in Indications
March 02, 2015
Taiho Submits TAS-102 (brand name in Japan: "Lonsurf® ") Marketing Authorization Application to the European Medicines Agency for the Treatment of Refractory Metastatic Colorectal Cancer
February 23, 2015
Taiho Pharmaceutical Announces TAS-102 (brand name in Japan: "Lonsurf® ") New Drug Application for Refractory Metastatic Colorectal Cancer Accepted for Review by FDA
January 05, 2015
Taiho Pharmaceutical Receives Approval to Manufacture and Market ZOSYN® 4.5 for I.V. Infusion Bag, an Injectable Antibiotic Combined with β-Lactamase Inhibitor
News Releases
Back Number
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008